IGFBP-2, His, Human
| $340.00 | |
| Z05408-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $340.00 | |
| Z05408-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 32.5 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 33-40 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of IGFBP-2, His, Human is greater than 95% as determined by SEC-HPLC. »
IGFBP-2, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, function, and activity of IGFs in the pericellular space. IGFBP2 is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Aberrant expression of IGFBP2 in cancer acts as a hub of an oncogenic network, integrating multiple cancer signaling pathways and serving as a potential therapeutic target for cancer treatment. |
| Synonyms | IBP-2; IGFBP-2; BP2; AI255832; mIGFBP-2; IGFBP2; IGF-BP53 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.